A Randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure and Reduced Ejection Fraction Who Are Intolerant of or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists (FINALITY-HF)
Latest Information Update: 14 Mar 2025
At a glance
- Drugs Finerenone (Primary)
- Indications Heart failure
- Focus Adverse reactions; Therapeutic Use
- Acronyms FINALITY-HF
Most Recent Events
- 11 Mar 2025 Planned End Date changed from 1 Jan 2028 to 1 Apr 2028.
- 11 Mar 2025 Planned primary completion date changed from 1 Aug 2026 to 1 Mar 2028.
- 17 Jan 2025 Status changed from not yet recruiting to recruiting.